WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles:
Related suggestion:
Alabama Barker, 18, shares racy bikiniUN chief calls for reform of global financial architecture, particularly with regard to debtValerie Bertinelli, 63, gushes over her 10Tesla's new mega factory project in Shanghai to start constructionZoe Saldana and husband Marco Perego look stylish in classic allJennifer Lopez, 54, shares sideSydney shopping mall reopens after stabbings. Police make first arrest in riot after church attackGolden Bachelor couple Gerry Turner and Theresa Nist reveal how her job impacted their marriageBruno Tonioli, 68, reveals he needs Botox after feeling 'wrinkly' next to Britain's Got Talent coCSX profit drops 10% despite railroad delivering 3% more freight in first quarter
3.7269s , 6497.34375 kb
Copyright © 2024 Powered by US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition ,Global Grounds news portal